{"filing":{"accession_number":"0001104659-26-094533","cik":"0001850119","ticker":"IPSC","company_name":"Century Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"tm2622911d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/tm2622911d1_8k.htm"},"events":[{"id":27064,"run_id":24635,"accession_number":"0001104659-26-094533","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Century Therapeutics issued a press release on August 12, 2026 announcing Q2 2026 financial results for the quarter ended June 30, 2026, disclosing cash position of $197.2 million, R\u0026D expenses of $19.6 million, G\u0026A expenses of $5.8 million, and net loss of $34.6 million, along with material business updates on pipeline programs CNTY-813 (pre-IND meeting completed, IND submission on track for 4Q 2026) and CNTY-308 (clinical trial planned for 2026).","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28431,"accession_number":"0001104659-26-094533","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Century Therapeutics issued a press release on August 12, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 results including cash position ($197.2M), R\u0026D expenses ($19.6M), G\u0026A expenses ($5.8M), and net loss ($34.6M). The filing explicitly states \"On August 12, 2026, Century Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended June 30, 2026\" and includes condensed consolidated statements of operations and balance sheets. This is a standard quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:13:43.902051+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28432,"accession_number":"0001104659-26-094533","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes an updated investor presentation (Exhibit 99.2) alongside a substantive earnings release (Exhibit 99.1) reporting Q2 2026 financial results, including cash position of $197.2 million, R\u0026D and G\u0026A expenses, and net loss of $34.6 million. The earnings release also discloses material business updates on CNTY-813 (pre-IND meeting with FDA, IND submission on track for 4Q 2026) and CNTY-308 (clinical trial planned for 2026). Although technically filed under Item 7.01 (Regulation FD Disclosure), the substance is a quarterly earnings release with financial statements and material development milestones that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:13:43.902051+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28431,"accession_number":"0001104659-26-094533","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Century Therapeutics issued a press release on August 12, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 results including cash position ($197.2M), R\u0026D expenses ($19.6M), G\u0026A expenses ($5.8M), and net loss ($34.6M). The filing explicitly states \"On August 12, 2026, Century Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended June 30, 2026\" and includes condensed consolidated statements of operations and balance sheets. This is a standard quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:13:43.902051+00:00","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-08-12"},{"id":28432,"accession_number":"0001104659-26-094533","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes an updated investor presentation (Exhibit 99.2) alongside a substantive earnings release (Exhibit 99.1) reporting Q2 2026 financial results, including cash position of $197.2 million, R\u0026D and G\u0026A expenses, and net loss of $34.6 million. The earnings release also discloses material business updates on CNTY-813 (pre-IND meeting with FDA, IND submission on track for 4Q 2026) and CNTY-308 (clinical trial planned for 2026). Although technically filed under Item 7.01 (Regulation FD Disclosure), the substance is a quarterly earnings release with financial statements and material development milestones that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:13:43.902051+00:00","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-08-12"}]}